Gynaecomastia associated with proton pump inhibitors: A case series from the Spanish pharmacovigilance system

Drug Safety

Volumn 30, Issue 6, 2007, Pages 527-531

  Carvajal, Alfonso ^a   Macias, Diego ^a   Gutiérrez, Angélica ^a   Ortega, Sara ^a   Sáinz, María ^a   Martín Arias, Luis H ^a   Velasco, Alfonso ^a  

^a UNIVERSITY OF VALLADOLID   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

LANSOPRAZOLE; OMEPRAZOLE; RABEPRAZOLE;

ADULT; AGED; ARTICLE; CASE STUDY; CLINICAL ARTICLE; DISEASE ASSOCIATION; DRUG EXPOSURE; DRUG SURVEILLANCE PROGRAM; DRUG WITHDRAWAL; FEMALE; GYNECOMASTIA; HUMAN; MALE; PRIORITY JOURNAL; SPAIN;

ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; AGED; AGED, 80 AND OVER; ANTI-ULCER AGENTS; DATABASES, FACTUAL; GYNECOMASTIA; HUMANS; MALE; MIDDLE AGED; ODDS RATIO; OMEPRAZOLE; PROTON PUMPS; RETROSPECTIVE STUDIES; SPAIN;

EID: 34249906144     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200730060-00006     Document Type: Article

References (24)

1. IMS [online]. Available from URL: http://www.imshealth.com. [Accessed 2006 July 31]
2. Wilton LV, Key C, Shakir SA. The pharmacovigilance of pantoprazole: the results of postmarketing surveillance on 11,541 patients in England. Drug Saf 2003; 26: 121-32
3. Martin RM, Dunn NR, Freemantle S, et al. The rates of common adverse events reported during treatment with proton pump inhibitors used in general practice in England: cohort studies. Br J Clin Pharmacol 2000; 50: 366-72
4. Santucci L, Farroni F, Fiorucci S, et al. Gynaecomastia during omeprazole therapy. N Engl J Med 1991; 324: 635
5. Convens C, Verhelst J, Mahler C. Painful gynaecomastia during omeprazole therapy. Lancet 1991; 338: 1153
6. Carvajal A, Martin Arias LH. Gynaecomastia and sexual disorders after the administration of omeprazole. Am J Gastroenterol 1995; 90 (6): 1028-9
7. Lindquist M, Edwards IR. Endocrine adverse effects of omeprazole. BMJ 1992; 305: 451-2
8. Adverse Drug Reactions Advisory Committee. Drug-induced gynaecomastia. Aust Adverse Drug React Bull 1997; 16: 3
9. Garcia Rodriguez LA, Jick H. Risk of gynaecomastia associated with cimetidine, omeprazole, and other antiulcer drugs. BMJ 1994; 308: 503-6
10. Álvarez Requejo A, Carvajal A, Begaud B, et al. Under-reporting of adverse drug reactions. Estimate based on a spontaneous reporting scheme and a sentinel system. Eur J Clin Pharmacol 1998; 54: 483-8
11. Karch FE, Lasagna L. Toward the operational identification of adverse drug reactions. Clin Pharmacol Ther 1977; 21: 247-54
12. International Monitoring of Adverse Reactions to Drugs. Adverse Reaction Terminology. Uppsala: World Health Organization Collaborating Centre for International Drug Monitoring, 1992
13. Evans SJW. Pharmacovigilance: a science or fielding emergencies? Stat Med 2000; 19: 3199-209
14. Rothman KJ, Lanes S, Sacks ST. The reporting odds ratio and its advantages over proportional reporting ratio. Pharmacoepidemiol Drug Saf 2004; 13: 519-23
15. van Puijenbroek EP, Bate A, Leufkens HG, et al. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol Drug Saf 2002; 11: 3-10
16. Egberts ACG, Meyboom RHB, van Puijenbroek EP. Use of measures of disproportionaly in pharmacovigilance. Three Dutch examples. Drug Saf 2002; 25: 453-8
17. Braunstein GD. Gynaecomastia. N Engl J Med 1993; 328: 490-5
18. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999; 341: 709-1
19. Satoh T, Munakata H, Fujita K, et al. Studies on the interactions between drug and estrogen: II. On the inhibitory effect of 29 drugs reported to induced gynaecomastia on the oxidation of estradiol at C-2 or C-17. Biol Pharm Bull 2003; 26: 695-700
20. Human Cytochrome P450 (CYP) Allele Nomenclature Committee [online]. Available from URL: http://www.cypalleles.ki.se/cyp2c19.htm. [Accessed 2006 July 31]
21. Goldstein JA, Ishizaki T, Chiba K, et al. Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations. Pharmacogenetics 1997; 7: 59-64
22. Desta Z, Zhao X, Shin JG, et al. Clinical significance of the cytochrome P4502C19 genetic polymorphism. Clin Pharmacokinet 2002; 41: 913-58
23. Claude K, Lardinois MD, Ernest L, et al. Cimetidine blocks testosterone synthesis. Arch Intern Med 1985; 154: 920-2
24. Satoh T, Itoh S, Seki T, et al. On the inhibitory action of 29 drugs having side effect gynecomastia on estrogen production. J Steroid Biochem Mol Biol 2002; 82: 209-16